145 results on '"Lues, Inge"'
Search Results
2. Development of the clinical candidate PBD-C06, a humanized pGlu3-Aβ-specific antibody against Alzheimer’s disease with reduced complement activation
3. Effector function of anti-pyroglutamate-3 Aβ antibodies affects cognitive benefit, glial activation and amyloid clearance in Alzheimer’s-like mice
4. An anti-pyroglutamate-3 Aβ vaccine reduces plaques and improves cognition in APPswe/PS1ΔE9 mice
5. A phase 1 study to evaluate the safety and pharmacokinetics of PQ912, a glutaminyl cyclase inhibitor, in healthy subjects
6. Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer’s disease: results of a randomized, double-blind, placebo-controlled phase 2a study
7. Combination of the Glutaminyl Cyclase Inhibitor PQ912 (Varoglutamstat) and the Murine Monoclonal Antibody PBD-C06 (m6) Shows Additive Effects on Brain Aβ Pathology in Transgenic Mice
8. Stereoselectivity of actions of the calcium sensitizer [+]-EMD 60263 and its enantiomer [-]-EMD 60264
9. P3-023: IN PURSUIT OF A SENSITIVE EEG FUNCTIONAL CONNECTIVITY OUTCOME MEASURE FOR CLINICAL TRIALS IN ALZHEIMER'S DISEASE
10. Passive Av immunotherapy: Current achievements and future perspectives
11. Immunohistochemical Evidence from APP-Transgenic Mice for Glutaminyl Cyclase as Drug Target to Diminish pE-Abeta Formation
12. Additional file 1: of Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimerâ s disease: results of a randomized, double-blind, placebo-controlled phase 2a study
13. Additional file 2: of Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimerâ s disease: results of a randomized, double-blind, placebo-controlled phase 2a study
14. I19 Normalization of phenotype and reduction of gliosis levels via glutaminyl cyclases inhibition in a huntington disease mouse model
15. P1‐099: COMBINATION OF A GLUTAMINYL CYCLASE INHIBITOR (PQ912) AND A PYROGLUTAMATE‐Aβ SPECIFIC ANTIBODY (PBD‐M06) SHOWS ADDITIVE EFFECTS IN A MOUSE MODEL WITH ALZHEIMER'S DISEASE‐LIKE PATHOLOGY
16. Passive Aβ Immunotherapy: Current Achievements and Future Perspectives
17. Immunohistochemical Evidence from APP-Transgenic Mice for Glutaminyl Cyclase as Drug Target to Diminish pE-Abeta Formation
18. Additional file 4: Figure S1. of Glutaminyl cyclase activity correlates with levels of Aβ peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimer’s disease patients
19. Additional file 3: Table S1. of Glutaminyl cyclase activity correlates with levels of Aβ peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimer’s disease patients
20. Glutaminyl cyclase activity correlates with levels of Aβ peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimer’s disease patients
21. Glutaminyl Cyclase Inhibitor PQ912 Improves Cognition in Mouse Models of Alzheimer’s Disease—Studies on Relation to Effective Target Occupancy
22. IN PURSUIT OF A SENSITIVE EEG FUNCTIONAL CONNECTIVITY OUTCOME MEASURE FOR CLINICAL TRIALS IN ALZHEIMER’S DISEASE
23. The pyroglutamate modification of toxic Aβ resulted new therapeutic aproaches: inhibitors of glutaminyl cyclase and highly specific antibodies – a status report
24. Phagocytic characterization and therapeutic efficacy of an anti-PyroGlutamate-3 Aβ IgG2a antibody in aged APP/PS1dE9 mice
25. COMBINATION OF A GLUTAMINYL CYCLASE INHIBITOR (PQ912) AND A PYROGLUTAMATE-Aβ SPECIFIC ANTIBODY (PBD-M06) SHOWS ADDITIVE EFFECTS IN A MOUSE MODEL WITH ALZHEIMER’S DISEASE-LIKE PATHOLOGY
26. Influence of hypo- and hyperthyroidism on plasma catecholamines in pithed rats
27. B-HT 920 acts as an α 1-adrenoceptor agonist in the rabbit aorta under certain in vitro conditions
28. Thyroid-dependent alterations of myocardial adrenoceptors and adrenoceptor-mediated responses in the rat
29. Effect of removing the endothelial cells on the reactivity of rat aortic segments to different α-adrenoceptor agonists
30. Postjunctional α-adrenoceptors in the isolated saphenous vein of the rabbit: Characterization and influence of angiotensin
31. Arginine phosphate in compound eyes
32. Facilitating interaction between rauwolscine and angiotensin in the mesenteric artery of the rabbit
33. Inhibitors of glutaminyl cyclase prevent pE-A beta mediated neurotoxicity: A new concept for the treatment of Alzheimer's disease
34. O1‐10‐02: TOXIC PGLU‐ABETA IS ENHANCED AND GLUTAMINYL CYCLASE (QC) UP‐REGULATED EARLY IN ALZHEIMER'S DISEASE (AD): INHIBITORS OF QC BLOCKING PGLU‐ABETA FORMATION ARE IN CLINICAL DEVELOPMENT
35. P1-333: Safety, pharmacokinetics and pharmacodynamics of PQ912, the first glutaminyl cyclase (QC) inhibitor to treat Alzheimer's disease, in healthy elderly
36. TOXIC PGLU-ABETA IS ENHANCED AND GLUTAMINYL CYCLASE (QC) UP-REGULATED EARLY IN ALZHEIMER'S DISEASE (AD): INHIBITORS OF QC BLOCKING PGLU-ABETA FORMATION ARE IN CLINICAL DEVELOPMENT
37. Three Thiadiazinone Derivatives, EMD 60417, EMD 66430, and EMD 66398, with Class III Antiarrhythmic Activity but Different Electrophysiologic Profiles
38. F&E bei Merck: Pharma
39. In Vivo Evidence of Positive Inotropism of EMD 57 033 Through Calcium Sensitization
40. Safety, pharmacokinetics and pharmacodynamics of PQ912, the first glutaminyl cyclase (QC) inhibitor to treat Alzheimer's disease, in healthy elderly
41. Nicht zu empfehlen: Verzicht auf Antikörper tierischen Urspungs?
42. Calcium Sensitization as a Positive Inotropic Mechanism in Diseased Rat and Human Heart
43. (6-oxo-3-pyridazinyl)-benzimidazoles as potent angiotensin II receptor antagonists
44. The Two Mechanisms of Action of Racemic Cardiotonic EMD 53998, Calcium Sensitization and Phosphodiesterase Inhibition, Reside in Different Enantiomers
45. A New Cardiotonic Drug Reduces the Energy Cost of Active Tension in Cardiac Muscle
46. The cardiotonic action of EMD 53 998 involves cyclic AMP-specific phosphorylation (PHOS) of troponin I (TNI) and phospholamban (PLB)
47. The transformation of a chromene derivative into benzofurans via allene intermediates
48. 3-Methyl-2H-1-benzopyran potassium channel activators
49. The Novel Cardiotonic Agent EMD 53 998 is a Potent “Calcium Sensitizer”
50. Novel Diazinone Derivatives Separate Myofilament Ca2+ Sensitization and Phosphodiesterase III Inhibitory Effects in Guinea Pig Myocardium.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.